Karyopharm CMO granted 32,415 RSUs

Karyopharm Therapeutics reported that its EVP & Chief Medical Officer, Reshma Rangwala, received an award of 32,415 restricted stock units (RSUs) of common stock on January 31, 2026 at a price of $0 per share.

Rhea-AI Filing Summary

Karyopharm Therapeutics reported that its EVP & Chief Medical Officer, Reshma Rangwala, received an award of 32,415 restricted stock units (RSUs) of common stock on January 31, 2026 at a price of $0 per share. The RSUs were granted under the company’s 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. Half of the shares vest on January 31, 2027, with the remaining half vesting on January 31, 2028. Following this award, Rangwala beneficially owns 61,805 shares of Karyopharm common stock directly.

Insider Trade Summary

Grant/Award: 32,415 shares

Grant/Award 1 txn

Insider Rangwala Reshma

Role EVP & Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,415	$0.00	$0.00

Holdings After Transaction: Common Stock — 61,805 shares (Direct)

Footnotes (1)

1. F1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karyopharm Therapeutics (KPTI) disclose in this Form 4 filing?

Karyopharm Therapeutics disclosed that EVP & Chief Medical Officer Reshma Rangwala received 32,415 restricted stock units of common stock. The grant was priced at $0 per share and was made under the company’s 2022 Equity Incentive Plan, increasing her direct beneficial ownership to 61,805 shares.

How many Karyopharm (KPTI) shares did Reshma Rangwala acquire in this transaction?

Reshma Rangwala acquired 32,415 restricted stock units of Karyopharm common stock in this transaction. These RSUs convert into common shares on a one-for-one basis and were granted at no cash cost to her, as reflected by the reported $0 price per share.

When do the newly granted KPTI restricted stock units vest for Reshma Rangwala?

The RSUs granted to Reshma Rangwala vest in two equal installments. Fifty percent of the 32,415 units vest on January 31, 2027, and the remaining 50% vest on January 31, 2028, subject to the terms of Karyopharm’s 2022 Equity Incentive Plan.

What is Reshma Rangwala’s total Karyopharm (KPTI) share ownership after this Form 4 transaction?

After the reported RSU award, Reshma Rangwala beneficially owns 61,805 shares of Karyopharm common stock directly. This total reflects her holdings following the grant of 32,415 restricted stock units reported in the Form 4 insider transaction filing.

Under which plan were the 32,415 KPTI restricted stock units granted?

The 32,415 restricted stock units were granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan allows the company to issue RSUs that convert into common stock on a one-for-one basis according to specified vesting schedules.

What role does the reporting person hold at Karyopharm Therapeutics (KPTI)?

The reporting person, Reshma Rangwala, serves as Karyopharm Therapeutics’ EVP & Chief Medical Officer. Her Form 4 filing reflects equity compensation in the form of restricted stock units linked to this executive officer position at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:31 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rangwala Reshma

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A		32,415(1)	A	$0	61,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

	/s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.